The Dystrophic Epidermolysis bullosa clinical pipeline comprises 20+ notable therapeutic agents in different stages of clinical development varying from Gene therapies, Cell therapies, RNA‐targeting ...

Please provide your email address to receive an email when new articles are posted on . Recessive dystrophic epidermolysis bullosa is a rare and serious condition. Zevaskyn is the first FDA-approved ...

Please provide your email address to receive an email when new articles are posted on . Pregabalin targets the a2-delta auxiliary subunit of voltage-gated calcium channels. Patients with RDEB in this ...

The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License Application (BLA) for prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis ...

Zevaskyn is supplied as a single-dose of up to 12 cellular sheets consisting of a patient's own viable, gene-modified cells that contain functional copies of the COL7A1 gene, which express collagen 7 ...

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with recessive dystrophic epidermolysis bullosa. The approval is based on the pivotal ...

The Food and Drug Administration (FDA) has approved a transformational treatment for one of the most tragic of pediatric skin diseases. The first-of-its kind topical gene therapy for Epidermolysis ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye. In 1999, I defined regenerative medicine as the collection of ...

Epidermolysis Bullosa: Types, Causes, Symptoms and Treatments: By Shreoshree Chakrabarty Epidermolysis Bullosa (EB) is a rare genetic disorder marked by extremely fragile skin that blisters or tears ...

As influencer Hannah Campbell mourns the death of her 10-month-old daughter, Elliana Rose, she is also doing her part to fight the disease that affected her baby girl. “Our sweet girl Elliana Rose ...